

NYRx Notice to Providers: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1) and Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Concurrent Therapy

February 5, 2026

The American College of Physicians and the American Diabetes Association recommend against the concurrent use of Glucagon-Like Peptide-1 (GLP-1) receptor agonists and Dipeptidyl Peptidase-4 (DPP-4) inhibitors as combination therapy does not provide additional glucose-lowering benefits.

Effective February 19, 2026, NYRx will implement pharmacy clinical edits that limit concurrent use of GLP-1 receptor agonists and DPP-4 inhibitors.

What Providers Need to Know

- NYRx covers medically necessary, FDA-approved drugs when used for Medicaid-covered indications.
- Weight loss is not a Medicaid-covered indication.

What Providers Need to Do

- Prescribers should consult current practice guidelines and prescribe a preferred GLP-1 or DPP-4 when appropriate. Concurrent utilization of drugs from these drug classes will result in pharmacy claim rejection.
- Pharmacists should review patient drug history and work with prescribers to avoid concurrent utilization of GLP-1 and DPP-4 drugs.

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.